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Abstract
Background: Informed consent (IC) is an ethical and legal prerequisite for trial participation, yet current approaches
evaluating participant understanding for IC during recruitment lack consistency. No validated measure has been
identified that evaluates participant understanding for IC based on their contributions during consent interactions.
This paper outlines the development and formative evaluation of the Participatory and Informed Consent (PIC)
measure for application to recorded recruitment appointments. The PIC allows the evaluation of recruiter information
provision and evidence of participant understanding.
Methods: Published guidelines for IC were reviewed to identify potential items for inclusion. Seventeen purposively
sampled trial recruitment appointments from three diverse trials were reviewed to identify the presence of items
relevant to IC. A developmental version of the measure (DevPICv1) was drafted and applied to six further recruitment
appointments from three further diverse trials to evaluate feasibility, validity, stability and inter-rater reliability. Findings
guided revision of the measure (DevPICv2) which was applied to six further recruitment appointments as above.
Results: DevPICv1 assessed recruiter information provision (detail and clarity assessed separately) and participant talk
(detail and understanding assessed separately) over 20 parameters (or 23 parameters for three-arm trials). Initial
application of the measure to six diverse recruitment appointments demonstrated promising stability and inter-rater
reliability but a need to simplify the measure to shorten time for completion. The revised measure (DevPICv2)
combined assessment of detail and clarity of recruiter information and detail and evidence of participant
understanding into two single scales for application to 22 parameters or 25 parameters for three-arm trials. Application
of DevPICv2 to six further diverse recruitment appointments showed considerable improvements in feasibility (e.g. time
to complete) with good levels of stability (i.e. test-retest reliability) and inter-rater reliability maintained.
Conclusions: The DevPICv2 provides a measure for application to trial recruitment appointments to evaluate quality of
recruiter information provision and evidence of patient understanding and participation during IC discussions. Initial
evaluation shows promising feasibility, validity, reliability and ability to discriminate across a range of recruiter practice
and evidence of participant understanding. More validation work is needed in new clinical trials to evaluate and refine
the measure further.
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Background
Informed consent (IC) is a legally and ethically established
prerequisite for trial participation that is enshrined in
international and national guidelines [1–3]. IC is defined
as having five elements, all of which are required for con-
sent to be regarded as legal and ethical: capacity, disclos-
ure, understanding, voluntariness and permission [4].
Whilst the content and quality of written patient informa-
tion is closely monitored by institutional review boards
and ethics committees [5–7], less attention is paid to
evaluating the quality of information provided in recruit-
ment appointments [8]. Yet, face-to-face discussion is of
pivotal importance in informed consent: systematic re-
views (SRs) have demonstrated its value for optimising
understanding during the consent process with the stron-
gest evidence for improved understanding associated with
extended discussion or enhanced Consent Forms [9, 10].
The most recent SR [9] highlighted the heterogeneity of
studies reviewed and called for the standardisation of ap-
proaches to evaluating IC and consistency in assessing
participant understanding for IC.
Existing methods for assessing participant understand-
ing for IC for research participation include participant
self-report via questionnaires [11–13] or structured tele-
phone interviews [14, 15] and evaluations of the recruit-
ment discussion [8]. Most rely on participant recall, but
vary in what they attempt to measure, including actual un-
derstanding [11, 13–15], perceived understanding [11, 12]
and satisfaction with the IC process [12, 14]. Frameworks
to encourage systematic implementation of best practice by
trial recruiters during consent interactions have also been
proposed [8, 16–20]. These set out to measure [8, 17] or
evaluate [19, 20] recruiter behaviour and propose models of
best practice during the interaction [8, 16, 17, 19], the ul-
timate goal being to improve participant understanding and
protect against coercion.
These frameworks evaluate the content and manner
in which recruiters provide information, but make no
attempt to measure participant understanding as dem-
onstrated in the interaction or extent of participation
in the conversation [4, 21]. Evidence over three de-
cades shows that both consent to, and refusal of, trial
participation continues to occur despite suboptimal
understanding by patients of what participation entails
[21–23]. Evidence continues to emerge that trial re-
cruitment is challenging [24] and essential trial con-
cepts, such as randomisation and equipoise, are often
not fully understood by trial participants [25–32]. Re-
cruiters need to be able to judge whether a participant
has understood the information provided [2] and this
judgement by the recruiter will usually be formed on
the basis of patient contributions during consent dis-
cussions. Evidence of participant understanding (or
misunderstanding) as it emerges during recruitment
appointments is, therefore, fundamental in evaluating
the quality of information provision by the recruiter. A
number of studies have shown that recruiters need
support to optimise their approaches to information
provision during recruitment [18–20, 25, 33–37]. A meas-
ure which aims to evaluate what and how information is
provided by recruiters and, at the same time, what evi-
dence there is of understanding by patients, will not only
provide evidence of patient understanding for the first
time, but also allow insight into recruiter behaviour that
may then be amenable to feedback and/or training to en-
sure that recruiters attend to patient understanding during
consent interactions.
We set out to develop a measure of IC that could be
applied to consent interactions taking place during re-
cruitment appointments (or recordings of these) to
evaluate the breadth and clarity of information provision
on key issues required for IC and also, more innova-
tively, to assess evidence of patient understanding and
participation during the interaction. The ultimate aim of
this work is to optimise participant understanding during
trial recruitment by improving recruiter practice during
informed consent discussions. This paper outlines the de-
velopment and formative evaluation of the Participatory
and Informed Consent (PIC) measure.
Methods
There were two stages in the development and formative
evaluation of the PIC measure: first, determining items for
inclusion; and second a two-phase formative evaluation.
Determining concepts for inclusion in the PIC measure
The following academic literature was reviewed to iden-
tify potential concepts for inclusion: published inter-
national and national guidelines on what information
should be understood by potential participants for IC to
be achieved [1–3, 5–7]; existing measures of understanding
for IC [8, 11–15]; and evaluative frameworks to guide re-
cruiters on what and how information should be conveyed
during trial recruitment appointments to promote shared
decision-making or patient-centred discussion about trial
participation [16–20]. From these reviews, an initial list of
concepts and potential items was derived (Table 1).
A purposive sample of 17 audio-recorded recruitment
appointments involving recruiters with a range of spe-
cialties and backgrounds (seven surgeons, two oncolo-
gists and eight nurses) from three trials [38–41]
(cancer/noncancer, two- and three-arm trials, including
surgical/nonsurgical arms) was selected to obtain a
wide range of appointment types including the out-
comes of accepted or refused random allocation of
treatment or being undecided and requesting further
time or consultation to support decision-making about
trial participation (Table 2).
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Two researchers with expertise in recruitment to trials
(JW and SP) analysed all 17 appointments independently
to identify the presence or absence of concepts identified
in Table 1 and to identify other concepts that seemed
relevant to the IC or interactional process. Findings were
compared and discrepancies discussed between JW and
SP to reach agreement.
Combining evidence from the academic literature re-
view and subsequent assessment of the practicability and
feasibility of evaluating audio-recordings of trial recruit-
ment appointments, a developmental version of the
measure was drawn up (DevPICv1, Additional file 1:
Appendix A). The measure was designed to be com-
pleted whilst listening to the audio-recording of the ap-
pointment with a transcript present if required.
Formative evaluation of the developmental PIC
Formative evaluation of the DevPIC was carried out it-
eratively in two phases.
Phase 1
The DevPICv1 (Additional file 1: Appendix A) was applied
to six further recruitment appointments from three differ-
ent trials [42–44] (Table 2). Appointments were purposively
sampled to include surgeon and oncologist recruiters, two-
and three-arm trials, with outcomes of trial participation
and refusal and where information provision was judged to
be ‘good’ or ‘less good’ by researchers involved in qualitative
research into trial recruitment (Table 2). The DevPICv1
was applied to appointments by two researchers (JW and
DE) blind to these categorisations. Both raters had expertise
in recruitment to trials. Raters were asked independently to
evaluate the feasibility, validity and reliability of the measure
in the following ways:
Feasibility: the time taken to apply the measure to each
recruitment appointment was recorded to determine
whether it was feasible to continue with it in its
existing format. It was assumed that a developmental
version should be completed in under an hour.
Validity: initial feedback on the face validity of the
measure was obtained through free-text comments and
feedback from the raters who completed it. Response
rates and missing data were identified for individual
items to evaluate their acceptability.
Reliability: inter-rater reliability was assessed by
evaluating differences in item responses made
independently by the two raters. Each rater was
required to rate each of 20 parameters (two-arm trials)
or 23 parameters (three-arm trials – see Additional
file 1: Appendix A) four times (evaluating first the
quantity then the clarity of recruiter information,
the quantity of patient talk and then evidence of
understanding shown in patient talk about each
parameter) giving a total of 80 ratings per appointment
(two-arm trials) or 92 ratings per appointment
(three-arm trials) respectively.
Stability: the stability (test-retest reliability) of the new
measure was assessed by evaluating changes in item
responses when the measure was applied to a single
appointment by the same researcher, with an interval of
at least 14 days. Rating procedure was as described for
inter-rater reliability.
In interpreting both reliability and stability, a
discrepancy of 1 point or less was deemed acceptable
on the grounds that this might represent the difference
between the presence and absence of information and
between ‘mostly clear’ and ‘very clear’ on the scale.
Larger discrepancies were noted.
Qualitative evaluation: free-text comments recorded
by raters on the content and interaction in the
recruitment appointment and the application of the
measure were collated. Thematic analysis [45]
was used to identify emergent themes in relation
to the content of the information and patterns of
interaction between recruiter and patient
(e.g. what and how much each contributed)
during discussion.
Table 1 Core concepts identified for inclusion in the
recruitment appointments
• Consultation purpose
• Relevant history, diagnosis and/or management to date
• Current management options (independent of study)
• Clinical Equipoise regarding trial treatments
• Research study purpose or question
• Trial arm 1 processes, disadvantages/risks, advantages/benefits
• Trial arm 2 processes, disadvantages/risks, advantages/benefits
• (3 arm trial only) Trial arm 3 processes, disadvantages/risks,
advantages/benefits
• Reason for trial or trial purpose
• Randomisation
◦ Reason for randomisation
◦ Process of randomisation
• Detail on trial treatment options
◦ Processes, potential risks and benefit
• Detail on trial procedures
◦ Potential risks/costs/burden & benefits of taking part,
◦ Options to refuse or withdraw,
◦ Options for further support in decision making about participation,
◦ Benefits to professional or organisation of P taking part.
◦ Confidentiality of data
◦ Explanation re compensation arrangements
Revised framework of core concepts following application to 17 recruitment
consultations from 3 diverse trials
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Findings from phase 1 were reviewed by a panel (JW,
DE, KNLA, JLD, RB) convened to revise and shorten
the measure to produce DevPICv2. In phase 2, it was
then applied by the same two researchers (JW and DE)
to six new appointments, purposively sampled as before
from three trials [38, 39, 43, 46], including two
appointments led by nurse recruiters, and again
including one appointment from each trial where
information provision was comprehensive and clear
and another where information provision was less
comprehensive and clear (Table 2). As before, raters
were blind to these categorisations.
Phase 2
Ratings were again compared to evaluate feasibility, val-
idity, response rates and missing data, inter-rater reli-
ability and stability (test-retest reliability) as described in
phase 1 above.
Reliability and Stability Each rater was required to rate
each of 22 parameters (two-arm trials, four appoint-
ments) or 25 parameters (three-arm trials, two appoint-
ments) twice, first evaluating the presence and clarity of
recruiter information and second evidence of under-
standing shown in patient talk about each parameter.
This gave a total of 138 comparisons evaluating recruiter
information and 138 comparisons evaluating evidence of
patient understanding respectively. As in phase one, a
discrepancy of 1 point or less was deemed acceptable on
the grounds that this might represent the difference be-
tween the presence and absence of information and be-
tween ‘mostly clear’ and ‘very clear’ on the scale. Larger
discrepancies were noted.
Free-text or narrative comments made during applica-
tion of the measure were collated and analysed themat-
ically as described above. In addition, concurrent validity
was assessed by applying another measure of recruiter
information provision for informed consent, the Process
and Quality of Informed Consent Instrument (P-QIC)
[8], to the same recruitment appointments. The P-QIC
evaluates recruiter information provision (rather than
both recruiter information provision and evidence of pa-
tient understanding) so domains measured in the P-QIC
were expected to map most closely onto the domains
measured in the recruiter information provision section
of the DevPICv2. The Spearman’s rank correlation was,
therefore, calculated between the total score on the P-
QIC and the total DevPICv2 score for recruiter informa-
tion provision.
Results
Determining items for inclusion in the DevPIC
Analysis of the initial 17 recruitment appointments re-
vealed wide variation in both whether and how concepts
identified within guidelines as a pre-requisite for the IC
process were presented and discussed during appoint-
ments. Guidelines identified concepts to be covered but
did not provide sufficient detail to enable consistency in
presentation during recruitment to trials in practice. The
broad stipulation that participants should understand
trial procedures [2, 3] was too general in that some re-
cruiters omitted basic concepts fundamental to rando-
mised controlled trial (RCT) participation, such as the
rationale for randomization, and there was evidence that
participants were confused by this. It also became appar-
ent that concepts identified in ethical frameworks [2]
foregrounded ethical priorities in protecting participant
rights and autonomy, but did not necessarily match the
specific information needs of individual participants. It
was noted that where participants contributed substan-
tively to the discussion, there was evidence that they cre-
ated meaning and understanding dynamically by
combining previous knowledge with new information
provided during discussion.
Concepts and items in the measure were revised to re-
flect these issues and particularly to include patient pri-
orities during the information exchange as identified in
these appointments and previous studies [18–20, 25, 47].
The first developmental version of the PIC (DevPICv1)
was, therefore, developed to take into account recruiter
and patient perspectives of the information required for
informed consent.
Formative evaluation of the DevPIC
Phase 1
Table 2 shows the characteristics of the six recruitment
appointments to which the measure was applied by two
researchers (JW and DE) during the first phase of evalu-
ation [42–44].
Feasibility of the measure Completion of the measure
took a mean of 117 min per appointment, and varied
from 75 to 169 min for those lasting between 17 min
and 40 min. Although raters felt that the time commit-
ment decreased as familiarity with the measure increased
this was longer than the hour limit set; therefore, the
measure needed to be reduced.
Validity of the measure Analysis of missing data for in-
dividual items showed no missing data in first applica-
tion of the measure by either rater, indicating good
acceptability of included items. Free-text comments pro-
vided by raters reported difficulty rating levels of patient
understanding.
Reliability of the measure Levels of inter-rater agree-
ment are shown in Table 3. Across the appointments,
inter-rater agreement showed a discrepancy of 1 point
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or less ranging between 113/126 (89.68%: patient talk)
and 89/126 (70.63%: patient understanding). Higher
levels of inter-rater agreement were observed for ratings
of quantity of recruiter information provision than for
ratings of clarity of recruiter information and for ratings
of how much a patient talked about a topic than for rat-
ings of their understanding (Table 3).
Stability of the measure Rates of test-retest or intra-
rater agreement are shown in Table 3. Across four ap-
pointments for two-arm trials and two appointments for
three-arm trials, test-retest agreement showed a discrep-
ancy of 1 point or less ranging between 124/126 (98.41%:
quantity of recruiter information provision and patient
talk) and 114/126 (90.48%: patient understanding, Table 3).
As with inter-rater agreement, higher levels of test-retest
agreement were observed for ratings of quantity of re-
cruiter information provision than for ratings of clarity
and for ratings of how much a patient talked about a topic
than for ratings of their understanding (Table 3).
Qualitative evaluation Free-text comments noted on
application of the measure during phase 1 of the evalu-
ation highlighted a number of issues. Time taken to
complete the measure needed to be reduced and it was
questioned whether a rater was able to judge levels of
patient understanding per se on the basis of evidence
emerging from the interaction. It was argued that a
more realistic option would be to rate only evidence of
understanding or misunderstanding. Recruiters who
were most successful in allowing evidence of under-
standing to emerge during the discussion facilitated sub-
stantive patient contributions to the discussion. They
also framed equipoise as providing the rationale for both
the trial and the random allocation of treatment to take
place.
Review of these findings by the panel resulted in the re-
vised version presented in Additional file 1: Appendix B.
Changes made to the measure were as follows:
1. Levels of recruiter detail and clarity of detail were
combined into a single scale so that raters were
able to rate presence/absence of information and
the level of clarity of that information within a
single 4-point scale (0 = absent, 1 = mostly unclear,
2 = mostly clear, 3 = very clear).
2. The two scales rating the level of detail found in
patient talk and levels of patient understanding were
also merged into a single 4-point scale. Feedback
from the qualitative evaluation was that raters
could not be expected to make a judgement on
participants’ levels of understanding but only to
judge levels of evidence of understanding. The
revised scale required a judgement about levels
of evidence of understanding (0 = evidence of
misunderstanding which was left unclarified by
the end of the appointment, 1 = no evidence of
understanding, 2 =minimal evidence of understanding,
Table 3 Phase 1 evaluation of inter-rater reliability and test-retest stability
Recruiter
info–quantity
Recruiter
info– clarity
Patient
talk–quantity
Patient
talk–understanding
Phase 1: inter-rater reliability
N of comparisons 126 126 126 126
N of comparisons showing ≤1-point
discrepancy (% of total comparisons)
111 (88.10) 92 (73.02) 113 (89.68) 89 (70.63)
N of comparisons showing 2-point discrepancy
(% of total comparisons)
13 (10.32) 5 (3.97) 10 (7.94) 7 (5.56)
N of comparisons showing ≥3-point discrepancy
(% of total comparisons)
2 (1.59) 29 (23.02)a 3 (2.38) 30 (23.81)a
aIncludes those comparisons where N/A
(coded 9) was marked for one application of
the measure and not the other
Phase 1: test-retest stability
N of comparisons 126 126 126 126
N of comparisons showing ≤1-point discrepancy
(% of total comparisons)
124 (98.41) 116 (92.06) 124 (98.41) 114 (90.48)
N of comparisons showing 2-point discrepancy
(% of total comparisons)
2 (1.59) 1 (0.79) 2 (1.59) 1 (0.79)
N of comparisons showing ≥3-point discrepancy
(% of total comparisons)a
0 (0.00) 9 (7.14)a 0 (0.00) 11 (8.73)a
aIncludes those comparisons where N/A (coded 9) was marked by one rater and not the other
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e.g. agreement tokens such as ‘ok’, ‘mm’, ‘I see’,
3 = substantive evidence of understanding which might
be provided by a patient comment, e.g. 'well he said it's
possible that it [RCT intervention] could cause a
stroke’).
3. Key content relevant for setting the trial in the
context of the patient’s diagnosis and decision-making
regarding treatments were brought together in
Section 2i, items 1–8 of the measure
(Additional file 1: Appendix B).
4. Items relating to processes of randomisation
(items 16, 17 and 18 Additional file 1: Appendix A)
were subsumed into a single item evaluating process of
randomisation (item 8, Additional file 1: Appendix B).
5. Four items were incorporated (Additional file 1:
Appendix B): item 4 assessed the presentation of
management options within the trial separately from
the management options available generally; item 23
assessed description of any benefits to the
professional should the patient choose participation;
item 24 assessed the description of measures to
protect patient confidentiality; and item 25 assessed
description of measures for patient compensation in
case of adverse events. All these items had been
previously implicitly assessed within other
parameters but were judged to need explicit
assessment in their own right.
6. A section containing four global judgements was
added to the measure (Additional file 1: Appendix B,
Section 3). Raters were required to judge whether
the recruiter consistently conveyed equipoise;
whether the patient was in equipoise by the end of
the appointment (or when any decision about
participation took place); whether the patient
accepted random allocation as a means to
determine treatment; and whether the patient
appeared sufficiently informed by the end of the
appointment (or when any decision about
participation took place) to make an informed
decision on participation. For each of these the
judgement was a binary choice between ‘yes’ or
‘no’ with the option to record that there was
insufficient evidence to make a judgement and
space for free-text comments.
7. Raters were invited to provide free-text comments
on the following aspects of the appointment: (1)
what the recruiter said, (2) how it was said and (3)
how it appeared to be understood by the participant
(Additional file 1: Appendix B, Section 4).
It was expected that these changes would result in
a substantial reduction in time taken to administer
the measure without reducing validity and inter-rater
reliability.
Phase 2
The DevPICv2 (Additional file 1: Appendix B) was ap-
plied to a further six diverse appointments [38, 39, 43,
46] (Table 2) to assess feasibility, validity, stability, inter-
rater reliability with a parallel qualitative assessment.
Feasibility Time taken to complete the DevPICv2 is
shown in Table 2. The mean completion time (56 min)
was less than half that recorded during phase 1.
Validity Analysis of missing data for individual items
showed no missing data in the first application of the
measure by either rater, indicating good acceptability of
included items. Spearman’s rank correlation between P-
QIC and the total score for DevPICv2 recruiter informa-
tion provision was 0.80 (p = 0.2).
Reliability Inter-rater reliability is shown in Table 4.
Inter-rater agreement showed a discrepancy of 1 point
or less in 125/138 (90.58%) of ratings of both recruiter
information provision and evidence of patient under-
standing (Table 4).
Stability of the measure Rates of test-retest or intra-
rater agreement are shown in Table 4. Test-retest agree-
ment showed a discrepancy of 1 point or less in 137/138
(99.28%) of ratings of both recruiter information
provision) and evidence of patient understanding
(Table 4).
Analysis of global judgements Ratings of global judge-
ments (Section 3) are shown in Table 5. Appointments 3
and 6 were judged by both raters to show sufficient un-
derstanding for informed consent; remaining appoint-
ments were judged to show insufficient evidence for
informed consent by both (2, 4 and 5) or one (1) rater.
When ratings on the global judgement ‘evidence of suffi-
cient understanding for informed consent’ were com-
pared to the DevPICv2 total scores for Sections 2i-2iii
across each appointment (Figs. 1 and 2) there was broad
agreement between ratings on the former and the latter.
DevPICv2 scores show appointments 3 and 6 scoring
highly and appointments 1, 2, 4 and 5 scoring more
poorly. A higher DevPICv2 score was recorded for ap-
pointment 5 on Section 2ii (describing treatment pro-
cesses, risks and benefits) but scores for this appointment
on Sections 2i and 2iii were comparable to appointments
1, 2 and 4.
Qualitative evaluation Comments in this section noted
that at times a brief summary of key information (evalu-
ated in Section 2i, DevPICv2) appeared more beneficial to
patient understanding than extensive detail about treat-
ment arms (evaluated in Section 2ii). Raters observed that
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evidence of understanding as created during conversation
could be distinguished from evidence of understanding
brought by patients and present from the outset. Evidence
for this could be detected in patient comments showing
awareness of issues that had not yet been discussed or
showing evidence of understanding emerging during
discussion.
Discussion
This study describes the development and formative
evaluation of a measure of participatory and informed
consent (PIC) for application to trial recruitment appoint-
ments to evaluate consent interactions for the content
and clarity of recruiter information provision and also the
extent to which evidence of patient understanding
emerges. Initial work identified concepts for inclusion in
the measure. This was followed by a two-phase evaluation:
phase 1 highlighted a need to shorten the measure to im-
prove feasibility, validity and reliability; and phase 2
showed considerable improvements in feasibility (e.g. time
to complete) stability (i.e. test-retest reliability) and inter-
rater reliability, suggesting that the measure is now ready
Table 4 Phase 2 evaluation of inter-rater reliability and test-retest stability
Recruiter information provision Evidence of patient understanding
Phase 2: inter-rater reliability
N of comparisons 138 138
N of comparisons showing ≤1-point discrepancy
(% of total comparisons)
125 (90.58) 125 (90.58)
N of comparisons showing 2-point discrepancy
(% of total comparisons)
10 (7.25) 13 (9.42)
N of comparisons showing ≥3-point discrepancy
(% of total comparisons)
3 (2.17) 0 (0.00)
Phase 2: test-retest stability
N of comparisons 138 138
N of comparisons showing ≤1-point discrepancy
(% of total comparisons)
137 (99.28) 137 (99.28)
N of comparisons showing 2-point discrepancy
(% of total comparisons)
0 (0.00) 1 (0.72)
N of comparisons showing ≥3-point discrepancy
(% of total comparisons)
1 (0.72) 0 (0.00)
Table 5 Global judgements from DevPICv2 Section 3
Appointment Rater Does the recruiter consistently
convey a position of equipoise
and what evidence do you have
to suggest this?
Is the P in equipoisea
and what evidence do
you have to suggest
this?
Does the patient accept
randomisation as a means to
determine treatmenta and
what evidence do you have
to support this?
Is there evidence that the
patient is sufficiently informed
by the end of the consultation
to make an informed decision
and what evidence do you have
to support this?
1 1 Y Unclear Unclear Unclear
2 Y Y Y Y
2 1 N Unclear Unclear N
2 N Y Unclear N
3 1 Y Y Unclear Y
2 Y Y Y Y
4 1 N Unclear N N
2 N Unclear N N
5 1 Y Unclear N Unclear
2 N Unclear N Unclear
6 1 Y Y Y Y
2 Y Y Y Y
aat the point of decision-making about participation or at the end of the appointment
Y = Yes, N = No, Unclear = insufficient evidence to make this judgement
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for a more comprehensive evaluation. The measure’s
novelty and value lie in its evaluation of evidence of pa-
tient understanding to place this at the forefront and as
the key variable for evaluating the immediate outcomes of
an IC discussion. It is now available for further validation
in the context of new clinical trials.
The ultimate goal of this work is to optimise informa-
tion provision by trial recruiters so that they are able to at-
tend to and maximise participant understanding during
consent interactions during recruitment. Participant un-
derstanding is an ethical prerequisite for recruiters taking
consent for trial participation and it should, therefore, be
in evidence during the IC discussion prior to consent or
refusal being given [2]. By evaluating evidence of under-
standing in the context where understanding is in part
created, the measure draws attention to the imperative for
the recruiter to have such evidence available, avoids prob-
lems with recall and allows us to identify approaches to
recruiter information provision that facilitate or inhibit
understanding. Such insights will be used to guide re-
cruiter training. Initial evaluation shows promising feasi-
bility, validity and reliability and evidence that the
measure is able to discriminate across a range of recruiter
practice and evidence of participant understanding.
Fig. 2 Mean total section scores for participant interaction
Fig. 1 Mean total section scores for recruiter information provision
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Previous measures of informed consent for research
have mainly used methods of participant reporting via
questionnaires or telephone interviews [11–15]. Such
measures enable identification of areas of understanding
(or lack of it) but do not offer insight on how or why
failures of understanding arise [10]. Failures of under-
standing may be the result of an issue not having been
discussed, not having been discussed clearly, having been
discussed but not properly understood, or recall problems.
One existing measure, the P-QIC [8], has attempted to
circumvent such issues by quantifying the IC process as it
occurs during consent discussions. The P-QIC shares the
advantages of the PIC of evaluating both content and
manner of information provision by the recruiter and cap-
turing this as it takes place, rather than as it is recalled by
the participant [8]. Relatively high correlations were found
between P-QIC and DevPICv2 scores for recruiter infor-
mation provision, implying that the P-QIC and the
DevPICv2 evaluate common domains in terms of content
and manner of recruiter information provision. However,
correlations did not reach significance, possibly due to the
small sample size. Furthermore the P-QIC does not evalu-
ate evidence of participant understanding in the inter-
action [8].
This study describes the development and formative
evaluation of the PIC; further evaluation is ongoing.
Mean time to complete the measure remained at just
under an hour per appointment during phase-2 evalu-
ation: for the measure to be feasible for application in
busy clinics it will benefit from further reduction in rater
burden. Evaluation to date has been small scale and data
on stability and reliability have been reported as percent-
age agreements rather than performing formal calcula-
tions (e.g. kappa statistics). Future evaluation should
include sociodemographic data on patients involved in
the recruitment appointments. However, the PIC evalu-
ates understanding for IC in a way that has not previ-
ously been attempted and an iterative developmental
process was most appropriate at this stage. There are
methodological challenges in attempting to measure evi-
dence of participant understanding (or misunderstanding)
based on their contributions to a discussion, e.g. assuming
understanding on the basis of a minimal response (e.g.
‘mm’ or ‘uhuh’) from the participant to information pre-
sented by the recruiter when they may have been func-
tioning as continuers, signalling ‘passive recipiency’ [48].
Insights from conversation analysis (CA) on achieving
understanding in interaction show that repeat utterances
or even statements such as ‘I understand’ are often
treated as only claiming, as opposed to evidencing un-
derstanding [49]. Further evidence may be needed to
confirm levels of patient understanding in addition to
the current DevPICv2 approach to evaluating these min-
imal responses. Reaching optimum understanding for IC
is best conceptualized as a process rather than a single
event [50] extending beyond a single recruitment ap-
pointment and involving discussions with different
health professionals and several sources of information
including formal and informal written information and
discussions with family and friends [51]. However, re-
cruitment appointments remain the focal point where
recruiters have an ethical imperative to explore and ad-
dress gaps in understanding and gain written informed
consent to participate. Although the measure has been
designed to be applied to a single IC appointment,
where multiple appointments occur for a single patient,
it could be applied repeatedly to capture differences
between appointments. Inevitably the measure’s value
depends on the rater having access to an audio- or
video-recording of the entire appointment and recordings
may be started late or recorders switched off with import-
ant discussion unrecorded. Our study employed audio-
recording which fails to capture nonverbal communication
which has not been included in our analysis.
Future development of the measure will include the
creation of a detailed coding manual with the aim of
increasing inter-rater reliability and evaluation of the
measure’s performance in additional trial contexts in a
full psychometric evaluation. Promising agreement was
shown in DevPICv2 between evaluation using Section
2i-iii and Section 3 and it may be that the measure can
be reduced further using Section 3 as a model; more
data are needed to determine relative validity of these
two sections. The measure currently incorporates a
qualitative narrative describing the interaction, adding
to the rater burden but providing useful insights into
issues that are highly relevant to optimizing patient
understanding. Future work will examine whether
these areas can be quantified. Preliminary evaluation
reported here showed variation in the extent to which
recruiter information provision conformed to stan-
dards identified in our measure and assumed to be
requisite for the IC process, indicating promising dis-
criminative validity and showing consistency with
other study findings [8]. It also showed variation in
the extent to which evidence of participant under-
standing emerged. We cannot claim that poor con-
formity with these standards of recruiter information
provision necessarily indicates a failed IC process.
Further research is needed to establish the relation-
ship between recruiter information provision and evi-
dence of patient understanding as measured by the
PIC, but also as measured by self-report measures of
IC. Nor is it clear whether individual items identified
in the PIC have disproportionately large impact on
patient understanding for trial participation; it cannot
be assumed that all items will have equal impact on
understanding for all individuals.
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The PIC was conceived as a formative measure of in-
formed consent, i.e. application of the measure will in-
form on areas of recruiter practice that can be modified
in order to benefit participant understanding for in-
formed consent. The measure provides a rapid method
of evaluating the breadth and clarity of information pro-
vided by recruiters in order to highlight areas where in-
formation is lacking or unclear with a view to feed this
information into training of recruiters. It was designed to
be applicable across trials and diseases so as to be max-
imally generalizable [52]. Our approach marks a move
away from a disclosure model of IC towards a participa-
tory model of IC which shares some of the premises of
shared decision-making [53]. It is important that re-
cruiters understand that engaging patients in discussion
about their preference is not coercive but can be an essen-
tial prerequisite for the informed consent process [47, 54].
Conclusion
The DevPICv2 provides a novel measure of IC that can
be applied directly to recruitment appointments where
trial participation is discussed in order to evaluate the
quality of recruiter information provision and, most im-
portantly for consent interactions, evidence of patient
understanding. Initial evaluation shows promising feasi-
bility, validity and reliability and evidence that the meas-
ure is able to discriminate across a range of recruiter
practice and evidence of participant understanding. Fur-
ther validation work is needed in new clinical trials to
evaluate and refine the measure further.
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